Trisomy 13
(Patau Syndrome; Trisomy D)
(See also Overview of Chromosomal Anomalies.)
Trisomy 13 occurs in about 1/10,000 live births; about 80% of cases are complete trisomy 13. Advanced maternal age increases the likelihood, and the extra chromosome is usually maternally derived.
Infants tend to be small for gestational age. Midline anomalies are common and include holoprosencephaly (failure of the forebrain to divide properly), facial anomalies such as cleft lip and cleft palate, microphthalmia, colobomas (fissures) of the iris, and retinal dysplasia. Supraorbital ridges are shallow, and palpebral fissures usually are slanted. The ears are abnormally shaped and usually low-set. Hearing loss is common. Scalp defects and dermal sinuses are also common. Loose folds of skin often are present over the back of the neck.
A single transverse palmar crease, polydactyly, and hyperconvex narrow fingernails are also common. About 80% of cases have severe congenital cardiovascular anomalies; dextrocardia is common. Genitals are frequently abnormal in both sexes; cryptorchidism and an abnormal scrotum occur in boys, and a bicornuate uterus occurs in girls.
Apneic spells in early infancy are frequent. Intellectual disability is severe.
Diagnosis
(See also Next-generation sequencing technologies.)
Diagnosis of trisomy 13 may be suspected postnatally by appearance or prenatally by abnormalities on ultrasonography (eg, intrauterine growth restriction), or by increased risk noted on multiple marker screening or noninvasive prenatal screening (NIPS) using cell-free fetal DNA sequences obtained from a maternal blood sample.
Confirmation is by cytogenetic testing (karyotyping, FISH analysis, and/or chromosomal microarray analysis) of samples obtained by chorionic villus sampling or amniocentesis. Postnatally, confirmation is by cytogenetic testing usually of a blood sample.
Confirmatory testing is offered in cases suspected based on NIPS. Management decisions, including termination of pregnancy, should not be made based on NIPS testing alone. See also The American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal–Fetal Medicine practice bulletin regarding cell-free fetal DNA testing.
Treatment
More Information
The following is an English-language resource that may be useful. Please note that THE MANUAL is not responsible for the content of this resource.
-
American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee: Practice bulletin on screening for fetal aneuploidy
